{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Malignancy&page=106", "query": { "condition": "Advanced Malignancy", "page": 106 }, "page_size": 10 }, "pagination": { "page": 106, "page_size": 10, "total_count": 9820, "total_pages": 982, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Malignancy&page=107&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Malignancy&page=105&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-12T22:37:10.013Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07124117", "title": "A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "OBI-902", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OBI Pharma, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 147, "start_date": "2025-08-04", "completion_date": "2029-02-08", "has_results": false, "last_update_posted_date": "2026-01-05", "last_synced_at": "2026-11-12T22:37:10.013Z", "location_count": 3, "location_summary": "La Jolla, California • Houston, Texas • San Antonio, Texas", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07124117" }, { "nct_id": "NCT03342417", "title": "Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer Female", "Ovarian Cancer", "Gastric Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "ExcellaBio LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2018-02-14", "completion_date": "2019-05-29", "has_results": false, "last_update_posted_date": "2021-11-09", "last_synced_at": "2026-11-12T22:37:10.013Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03342417" }, { "nct_id": "NCT01987726", "title": "Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid Tumors", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Recurrent Breast Cancer", "Recurrent Colon Cancer", "Recurrent Rectal Cancer", "Stage IV Breast Cancer", "Stage IVA Colon Cancer", "Stage IVA Rectal Cancer", "Stage IVB Colon Cancer", "Stage IVB Rectal Cancer" ], "interventions": [ { "name": "cytology specimen collection procedure", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2013-09-03", "completion_date": "2021-06-28", "has_results": false, "last_update_posted_date": "2021-10-28", "last_synced_at": "2026-11-12T22:37:10.013Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01987726" }, { "nct_id": "NCT01092585", "title": "Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Tesetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genta Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2010-02", "completion_date": "2012-03", "has_results": false, "last_update_posted_date": "2011-11-08", "last_synced_at": "2026-11-12T22:37:10.013Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01092585" }, { "nct_id": "NCT01834235", "title": "QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer, Adult" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "NPC-1C", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Precision Biologics, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 81, "start_date": "2013-04", "completion_date": "2019-12", "has_results": true, "last_update_posted_date": "2025-05-07", "last_synced_at": "2026-11-12T22:37:10.013Z", "location_count": 12, "location_summary": "San Francisco, California • New Haven, Connecticut • Miami, Florida + 7 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01834235" }, { "nct_id": "NCT04866017", "title": "A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Ociperlimab", "type": "DRUG" }, { "name": "Chemotherapy", "type": "DRUG" }, { "name": "Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2021-06-17", "completion_date": "2023-10-17", "has_results": true, "last_update_posted_date": "2024-10-31", "last_synced_at": "2026-11-12T22:37:10.013Z", "location_count": 1, "location_summary": "Bolivar, Missouri", "locations": [ { "city": "Bolivar", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04866017" }, { "nct_id": "NCT05840510", "title": "Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult", "NSCLC", "Advanced Cancer", "Metastatic Cancer", "Malignant Neoplastic Disease" ], "interventions": [ { "name": "Adagrasib", "type": "DRUG" }, { "name": "nab-Sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mirati Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2023-08-07", "completion_date": "2024-12-27", "has_results": false, "last_update_posted_date": "2025-04-25", "last_synced_at": "2026-11-12T22:37:10.013Z", "location_count": 3, "location_summary": "Cleveland, Ohio • Nashville, Tennessee • Houston, Texas", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05840510" }, { "nct_id": "NCT00139620", "title": "A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "Tarceva, erlotinib, OSI-774", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OSI Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2005-08-22", "completion_date": "2007-06-25", "has_results": false, "last_update_posted_date": "2018-02-08", "last_synced_at": "2026-11-12T22:37:10.013Z", "location_count": 4, "location_summary": "Santa Monica, California • Aurora, Colorado • Rochester, Minnesota + 1 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00139620" }, { "nct_id": "NCT02453620", "title": "Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Breast Adenocarcinoma", "Invasive Breast Carcinoma", "Malignant Solid Neoplasm" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Blood Sample", "type": "OTHER" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Entinostat", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pharmacogenomic Study", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "OTHER", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2016-02-12", "completion_date": "2027-09-11", "has_results": false, "last_update_posted_date": "2026-11-12", "last_synced_at": "2026-11-12T22:37:10.013Z", "location_count": 5, "location_summary": "Duarte, California • New Haven, Connecticut • Baltimore, Maryland + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02453620" }, { "nct_id": "NCT03775850", "title": "A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer Metastatic", "Triple Negative Breast Cancer", "Non Small Cell Lung Cancer", "Bladder Cancer", "GastroEsophageal Cancer", "Renal Cell Carcinoma", "MSI-H" ], "interventions": [ { "name": "EDP1503", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Evelo Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 69, "start_date": "2018-12-19", "completion_date": "2021-10-31", "has_results": false, "last_update_posted_date": "2023-03-24", "last_synced_at": "2026-11-12T22:37:10.013Z", "location_count": 5, "location_summary": "Rogers, Arkansas • Sarasota, Florida • Oklahoma City, Oklahoma + 2 more", "locations": [ { "city": "Rogers", "state": "Arkansas" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Chattanooga", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03775850" } ] }